1. Home
  2. VERX vs MESO Comparison

VERX vs MESO Comparison

Compare VERX & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vertex Inc.

VERX

Vertex Inc.

HOLD

Current Price

$12.94

Market Cap

2.2B

Sector

Technology

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$14.27

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VERX
MESO
Founded
1978
2004
Country
United States
Australia
Employees
N/A
81
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
VERX
MESO
Price
$12.94
$14.27
Analyst Decision
Buy
Strong Buy
Analyst Count
12
1
Target Price
$24.25
N/A
AVG Volume (30 Days)
1.8M
175.9K
Earning Date
05-07-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$748,444,000.00
N/A
Revenue This Year
$12.78
$629.74
Revenue Next Year
$11.61
$30.65
P/E Ratio
$302.25
N/A
Revenue Growth
12.25
N/A
52 Week Low
$10.21
$10.32
52 Week High
$36.75
$21.50

Technical Indicators

Market Signals
Indicator
VERX
MESO
Relative Strength Index (RSI) 57.04 49.97
Support Level $12.41 $13.91
Resistance Level $13.73 $16.06
Average True Range (ATR) 0.62 0.40
MACD 0.15 -0.01
Stochastic Oscillator 91.03 47.08

Price Performance

Historical Comparison
VERX
MESO

About VERX Vertex Inc.

Vertex Inc is a provider of tax technology and services. Its software, content, and services help customers stay in compliance with indirect taxes that occur in taxing jurisdictions all over the world. It provides cloud-based and on-premise solutions to specific industries for every line of tax, including income, sales, consumer use, value-added, and payroll. The company offers solutions such as tax determination, Tax Data Management, document management, and compliance and reporting, among others. The company derives revenue from software subscriptions.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: